For lumpectomy surgeries, many small, early-stage tumors can’t be felt by hand during an exam, which makes them difficult to […]
Category: BME Spotlight Faculty
New device could make lumpectomies faster and more precise
BME Professor Irving Bigio is being recognized by the Evans Center for Interdisciplinary Biomedical Research, at the BU School of […]
Three ENG researchers, Assistant Professor Mary Dunlop, Assistant Professor Wilson Wong, and Professor Ji-Xin Cheng, were awarded a three-year, $1.5M Department of Energy grant to develop technology to better understand and measure the synthesis of biofuels in living cells.
Assistant Professor Allyson Sgro (BME) has been awarded a two-year grant under the National Science Foundation’s (NSF) 10 Big Ideas program to elucidate how cells work together to form groups.
Two ENG professors have been awarded nearly $1 million from the National Science Foundation (NSF) as part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative. Principal Investigator Associate Professor Kamal Sen (BME) and Co-Principal Investigator Associate Professor Xue Han (BME) will study the neural networks that allow the brain to distinguish sounds from each other.
BU was named one of the most innovative national universities for the first time in the 2019 US News & World Report Best Colleges rankings, out today. “I think there’s a general understanding that the world of higher education is changing rapidly,” says Gerald Fine (MSE, ME). “The leadership of the University has created an environment where experimentation in better ways to educate students is encouraged.”
Only three percent of members become fellows and to be nominated and elected, a member must meet qualifications in at least one of nine categories; Zhang was chosen for her accomplishments in the research and education categories.
Joyce Wong (BME, MSE) and Eric Kolaczyk (CAS, SE) were elected 2017 Fellows of the American Association for the Advancement of Science.
Researchers have come up with a tool that offers a means of control over engineered cells, and it comes from a seemingly unlikely source: the hepatitis C genome. In combination with a widely available antiviral medication, the new system offers a novel tool: a highly specific way to turn engineered cells on and off, with an existing, proven medication.